Neurometrix Inc (NURO) 1.66 $NURO
NeuroMetrix Reports Recent Media Coverage for Quell
BusinessWire - Thu Jul 28, 1:11PM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) today reported continued strong media attention focusing on the company's innovative Quell(R) Wearable Pain Relief Technology(TM). Highlights include:
NURO: 1.66 (+0.06)
NeuroMetrix, Inc. Announces Date for 2016 Second Quarter Financial Results Conference Call
BusinessWire - Thu Jul 14, 6:00AM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2016 second quarter financial results before the opening of the market on Thursday July 21, 2016. The Company will host a conference call at 8:00 a.m., Eastern Time on July 21, 2016 to discuss its financial results as well as business developments affecting the Company.
NURO: 1.66 (+0.06)
NeuroMetrix' Quell Device Makes Second Appearance at the American Podiatric Medical Association Annual Scientific Meeting
BusinessWire - Tue Jul 12, 10:00AM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell(R) Wearable Pain Relief Technology(TM) will be featured for the second year in a row at the American Podiatric Medical Association's Annual Scientific Meeting to be held July 14-17 in Philadelphia.
NURO: 1.66 (+0.06)
NeuroMetrix Announces Launch of Quell Sport Electrode
BusinessWire - Thu Jul 07, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) today announced commercial launch of a new Sport Electrode for its innovative Quell(R) Wearable Pain Relief Technology(TM). The new electrode has a special hydrogel designed to better hold up in situations with high humidity and perspiration. The Sport Electrode absorbs less moisture, but is otherwise comparable to the original Quell Electrode. It is available at QuellRelief.com.
NURO: 1.66 (+0.06)
NeuroMetrix Submits CE Mark Application for Quell Wearable Pain Relief Device
BusinessWire - Wed Jun 22, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that a CE (Conformite Europeenne) Technical File Application for Quell(R) has been submitted to TA deg V SA deg D Product Service GmbH, which is one of the Notified Bodies responsible for reviewing and approving new products. This regulatory filing seeks QuellCE certification in the European Union as a class IIa medical device, as defined by the Medical Device Directive (93/42/EEC). CE certification or "CE Marking" will allow Quellto be marketed directly to consumers within the European Union.
NURO: 1.66 (+0.06)
NeuroMetrix Showcases Quell Technology at the Western Foot & Ankle Conference
BusinessWire - Tue Jun 21, 6:00AM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell(R) Wearable Pain Relief Technology(TM) will be featured at the Western Foot & Ankle Conference to be held June 23-26 in Anaheim, CA.
NURO: 1.66 (+0.06)
NeuroMetrix Announces Quell Distribution in Canada
BusinessWire - Tue Jun 14, 1:26PM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Quell(R) Wearable Pain Relief Technology(TM) is available in Canada via Amazon Canada.
NURO: 1.66 (+0.06)
NeuroMetrix Reports Executive Stock Transactions during May 2016
BusinessWire - Fri Jun 10, 10:31AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) which developed and markets Quell(R) Wearable Pain Relief Technology(TM), reported purchases during May 2016 of the company's common stock by its Chief Executive Officer, Dr. Shai N. Gozani; its Chief Financial Officer, Thomas T. Higgins; and its SVP and General Manager, Consumer, Frank McGillin. Details of these transactions may be found on the U.S. Securities and Exchange Commission's EDGAR website at the following links:
NURO: 1.66 (+0.06)
NeuroMetrix Showcases Quell Technology at SLEEP 2016, the 30th Anniversary Meeting of the Associated Professional Sleep Societies
BusinessWire - Thu Jun 09, 6:00AM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell(R) Wearable Pain Relief Technology(TM) will be featured at SLEEP 2016, which is a joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society. The meeting takes place June 11-15 in Denver, CO.
NURO: 1.66 (+0.06)
NeuroMetrix Closes $21.3 Million At-The-Market Private Placement of Preferred Stock and Warrants and Redeems $13.8 Million of Outstanding Preferred Stock
BusinessWire - Wed Jun 08, 3:27PM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) reported that it has closed its previously announced private placement of preferred stock and warrants. The Company sold to a healthcare dedicated institutional investor 21,300 shares of Series D convertible preferred stock at a price of $1,000 per share, and warrants to purchase an aggregate of approximately 11.8 million shares of common stock at an exercise price of $1.69 per share. The convertible preferred stock is convertible into 11.8 million shares of common stock at a conversion price of $1.805 per share, subject to certain ownership limitations.
NURO: 1.66 (+0.06)
NeuroMetrix Celebrates 20 Year Anniversary
BusinessWire - Mon Jun 06, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it is celebrating its twenty year anniversary.
NURO: 1.66 (+0.06)
NeuroMetrix Announces $21.3 Million at the Market Private Placement of Preferred Stock and Warrants
BusinessWire - Thu Jun 02, 3:19PM CDT
NeuroMetrix, Inc. (NASDAQ: NURO) announced today that it entered into a definitive securities purchase agreement with a healthcare dedicated institutional investor in connection with a private placement of 21,300 shares of Series C convertible preferred stock at a price of $1,000 per share and warrants to purchase an aggregate of approximately 11.8 million shares of common stock at an exercise price of $1.69 per share. The Company expects to receive gross proceeds from the offering of $21.3 million and it is expected that approximately $13.8 million of the proceeds of the offering will be used to redeem 13,800 shares of Series C convertible preferred stock held by the healthcare dedicated institutional investor and the balance of the proceeds will be used for general working capital purposes.
NURO: 1.66 (+0.06)
NeuroMetrix Announces Availability of Quell in Approximately 1,000 Chain Drug Stores
BusinessWire - Thu Jun 02, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Quell(R) will be available, beginning in June 2016, in approximately 1,000 chain drug stores as part of a retail test with the two largest US drug retailers.
NURO: 1.66 (+0.06)
NeuroMetrix to Present at the LD Micro Invitational Conference on June 7, 2016
BusinessWire - Tue May 31, 10:00AM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the upcoming LD Micro Invitational at the Luxe Sunset Bel Air Hotel in Los Angeles, CA. Dr. Gozani intends to provide an update on the Company's business activities including the Quell(R) Wearable Pain Relief device.
NURO: 1.66 (+0.06)
NeuroMetrix Reports the Launch of the Quell(R) Health Cloud for Android
BusinessWire - Thu May 26, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), announced today the launch of the Quell Health Cloud for Android The updated Android app allows consumers to set up accounts on the Quell Health Cloud where their data is automatically backed-up to secure storage. This eliminates consumer worry about losing their therapy or sleep data, and allows them to review their data on multiple mobile devices. With the updated launch users of both the Android and iOS apps can tap into the Health Cloud capabilities.
NURO: 1.66 (+0.06)
NeuroMetrix Announces Frank McGillin, SVP and General Manager, Consumer to participate in a Digital Health Summer Summit Panel at BIO 2016
BusinessWire - Wed May 18, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) announced that Frank McGillin, Senior Vice President and General Manager, Consumer will participate in a panel discussion entitled "The Rise of Enterprise & Condition-Specific Wearables" during the Fifth Annual Digital Health Summer Summit. Digital Health is co-located with the 2016 Bio International Convention at the Moscone Center in San Francisco and the panel discussion will be held on Tuesday, June 7 at 11:15am (Pacific).
NURO: 1.66 (+0.06)
NeuroMetrix Announces Availability of Quell at Brookstone.com
BusinessWire - Mon May 16, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq:NURO) announced today that Quell(R) is now available at Brookstone.com.
NURO: 1.66 (+0.06)
NeuroMetrix Announces Launch of National TV Campaign to Support Quell
BusinessWire - Thu May 12, 10:43AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) has launched national television advertising to promote the company's innovative Quell(R) Wearable Pain Relief Technology(TM). The high impact campaign will air nationally, including major news networks such as Fox News, MSNBC and CNBC. The ads feature Natalie Strand, MD, a noted pain management expert who describes the technology as "a paradigm shift in chronic pain relief."
NURO: 1.66 (+0.06)
NeuroMetrix to Present at First Look Equities Summit
BusinessWire - Fri Apr 22, 10:01AM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) announced today that Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the First Look Equities Summit at the City Club of Buckhead in Atlanta, GA on April 26, 2016. Dr. Gozani intends to provide an update on the Company's business activities including the Quell(R) Wearable Pain Relief Technology(TM).
NURO: 1.66 (+0.06)
NeuroMetrix Reports Q1 2016 Financial Results and Highlights
BusinessWire - Thu Apr 21, 6:00AM CDT
--8,138 Quell(R) Devices Shipped
NURO: 1.66 (+0.06)
NeuroMetrix Reports Recent Media Coverage for Quell
BusinessWire - Thu Jul 28, 1:11PM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) today reported continued strong media attention focusing on the company's innovative Quell(R) Wearable Pain Relief Technology(TM). Highlights include:
NURO: 1.66 (+0.06)
NeuroMetrix, Inc. Announces Date for 2016 Second Quarter Financial Results Conference Call
BusinessWire - Thu Jul 14, 6:00AM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2016 second quarter financial results before the opening of the market on Thursday July 21, 2016. The Company will host a conference call at 8:00 a.m., Eastern Time on July 21, 2016 to discuss its financial results as well as business developments affecting the Company.
NURO: 1.66 (+0.06)
NeuroMetrix' Quell Device Makes Second Appearance at the American Podiatric Medical Association Annual Scientific Meeting
BusinessWire - Tue Jul 12, 10:00AM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell(R) Wearable Pain Relief Technology(TM) will be featured for the second year in a row at the American Podiatric Medical Association's Annual Scientific Meeting to be held July 14-17 in Philadelphia.
NURO: 1.66 (+0.06)
NeuroMetrix Announces Launch of Quell Sport Electrode
BusinessWire - Thu Jul 07, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) today announced commercial launch of a new Sport Electrode for its innovative Quell(R) Wearable Pain Relief Technology(TM). The new electrode has a special hydrogel designed to better hold up in situations with high humidity and perspiration. The Sport Electrode absorbs less moisture, but is otherwise comparable to the original Quell Electrode. It is available at QuellRelief.com.
NURO: 1.66 (+0.06)
NeuroMetrix Submits CE Mark Application for Quell Wearable Pain Relief Device
BusinessWire - Wed Jun 22, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that a CE (Conformite Europeenne) Technical File Application for Quell(R) has been submitted to TA deg V SA deg D Product Service GmbH, which is one of the Notified Bodies responsible for reviewing and approving new products. This regulatory filing seeks QuellCE certification in the European Union as a class IIa medical device, as defined by the Medical Device Directive (93/42/EEC). CE certification or "CE Marking" will allow Quellto be marketed directly to consumers within the European Union.
NURO: 1.66 (+0.06)
NeuroMetrix Showcases Quell Technology at the Western Foot & Ankle Conference
BusinessWire - Tue Jun 21, 6:00AM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell(R) Wearable Pain Relief Technology(TM) will be featured at the Western Foot & Ankle Conference to be held June 23-26 in Anaheim, CA.
NURO: 1.66 (+0.06)
NeuroMetrix Announces Quell Distribution in Canada
BusinessWire - Tue Jun 14, 1:26PM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Quell(R) Wearable Pain Relief Technology(TM) is available in Canada via Amazon Canada.
NURO: 1.66 (+0.06)
NeuroMetrix Reports Executive Stock Transactions during May 2016
BusinessWire - Fri Jun 10, 10:31AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) which developed and markets Quell(R) Wearable Pain Relief Technology(TM), reported purchases during May 2016 of the company's common stock by its Chief Executive Officer, Dr. Shai N. Gozani; its Chief Financial Officer, Thomas T. Higgins; and its SVP and General Manager, Consumer, Frank McGillin. Details of these transactions may be found on the U.S. Securities and Exchange Commission's EDGAR website at the following links:
NURO: 1.66 (+0.06)
NeuroMetrix Showcases Quell Technology at SLEEP 2016, the 30th Anniversary Meeting of the Associated Professional Sleep Societies
BusinessWire - Thu Jun 09, 6:00AM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell(R) Wearable Pain Relief Technology(TM) will be featured at SLEEP 2016, which is a joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society. The meeting takes place June 11-15 in Denver, CO.
NURO: 1.66 (+0.06)
NeuroMetrix Closes $21.3 Million At-The-Market Private Placement of Preferred Stock and Warrants and Redeems $13.8 Million of Outstanding Preferred Stock
BusinessWire - Wed Jun 08, 3:27PM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) reported that it has closed its previously announced private placement of preferred stock and warrants. The Company sold to a healthcare dedicated institutional investor 21,300 shares of Series D convertible preferred stock at a price of $1,000 per share, and warrants to purchase an aggregate of approximately 11.8 million shares of common stock at an exercise price of $1.69 per share. The convertible preferred stock is convertible into 11.8 million shares of common stock at a conversion price of $1.805 per share, subject to certain ownership limitations.
NURO: 1.66 (+0.06)
NeuroMetrix Celebrates 20 Year Anniversary
BusinessWire - Mon Jun 06, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it is celebrating its twenty year anniversary.
NURO: 1.66 (+0.06)
NeuroMetrix Announces $21.3 Million at the Market Private Placement of Preferred Stock and Warrants
BusinessWire - Thu Jun 02, 3:19PM CDT
NeuroMetrix, Inc. (NASDAQ: NURO) announced today that it entered into a definitive securities purchase agreement with a healthcare dedicated institutional investor in connection with a private placement of 21,300 shares of Series C convertible preferred stock at a price of $1,000 per share and warrants to purchase an aggregate of approximately 11.8 million shares of common stock at an exercise price of $1.69 per share. The Company expects to receive gross proceeds from the offering of $21.3 million and it is expected that approximately $13.8 million of the proceeds of the offering will be used to redeem 13,800 shares of Series C convertible preferred stock held by the healthcare dedicated institutional investor and the balance of the proceeds will be used for general working capital purposes.
NURO: 1.66 (+0.06)
NeuroMetrix Announces Availability of Quell in Approximately 1,000 Chain Drug Stores
BusinessWire - Thu Jun 02, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Quell(R) will be available, beginning in June 2016, in approximately 1,000 chain drug stores as part of a retail test with the two largest US drug retailers.
NURO: 1.66 (+0.06)
NeuroMetrix to Present at the LD Micro Invitational Conference on June 7, 2016
BusinessWire - Tue May 31, 10:00AM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the upcoming LD Micro Invitational at the Luxe Sunset Bel Air Hotel in Los Angeles, CA. Dr. Gozani intends to provide an update on the Company's business activities including the Quell(R) Wearable Pain Relief device.
NURO: 1.66 (+0.06)
NeuroMetrix Reports the Launch of the Quell(R) Health Cloud for Android
BusinessWire - Thu May 26, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), announced today the launch of the Quell Health Cloud for Android The updated Android app allows consumers to set up accounts on the Quell Health Cloud where their data is automatically backed-up to secure storage. This eliminates consumer worry about losing their therapy or sleep data, and allows them to review their data on multiple mobile devices. With the updated launch users of both the Android and iOS apps can tap into the Health Cloud capabilities.
NURO: 1.66 (+0.06)
NeuroMetrix Announces Frank McGillin, SVP and General Manager, Consumer to participate in a Digital Health Summer Summit Panel at BIO 2016
BusinessWire - Wed May 18, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) announced that Frank McGillin, Senior Vice President and General Manager, Consumer will participate in a panel discussion entitled "The Rise of Enterprise & Condition-Specific Wearables" during the Fifth Annual Digital Health Summer Summit. Digital Health is co-located with the 2016 Bio International Convention at the Moscone Center in San Francisco and the panel discussion will be held on Tuesday, June 7 at 11:15am (Pacific).
NURO: 1.66 (+0.06)
NeuroMetrix Announces Availability of Quell at Brookstone.com
BusinessWire - Mon May 16, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq:NURO) announced today that Quell(R) is now available at Brookstone.com.
NURO: 1.66 (+0.06)
NeuroMetrix Announces Launch of National TV Campaign to Support Quell
BusinessWire - Thu May 12, 10:43AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) has launched national television advertising to promote the company's innovative Quell(R) Wearable Pain Relief Technology(TM). The high impact campaign will air nationally, including major news networks such as Fox News, MSNBC and CNBC. The ads feature Natalie Strand, MD, a noted pain management expert who describes the technology as "a paradigm shift in chronic pain relief."
NURO: 1.66 (+0.06)
NeuroMetrix to Present at First Look Equities Summit
BusinessWire - Fri Apr 22, 10:01AM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) announced today that Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the First Look Equities Summit at the City Club of Buckhead in Atlanta, GA on April 26, 2016. Dr. Gozani intends to provide an update on the Company's business activities including the Quell(R) Wearable Pain Relief Technology(TM).
NURO: 1.66 (+0.06)
NeuroMetrix Reports Q1 2016 Financial Results and Highlights
BusinessWire - Thu Apr 21, 6:00AM CDT
--8,138 Quell(R) Devices Shipped
NURO: 1.66 (+0.06)
